Novo is currently in a golden age of growth. Over the last five years, its trailing-12-month revenue grew by 109%, reaching $39.3 billion, thanks to its portfolio of potent drugs for cardiometabolic illnesses like diabetes and obesity.

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare price negotiations for 2027, the U.S. government said on Friday. Other drugs on the list include Pfizer's cancer drugs Ibrance and Xtandi,

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare price negotiations for 2027, the U.S. government said on Friday, part of a law pharmaceutical companies have pledged to revisit with the Trump administration.

Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight patients lower their weight by 20.7%. The trial was testing a 7.2 milligram dose of the drug,

Danish businesses are concerned about a possible trade conflict with the United States over Greenland, a major lobby group said on Thursday after business leaders, including CEO of obesity drugmaker Novo Nordisk,

Luxury bellwether regains crown as drugmaker slips on concerns it will have to cut weight loss medication prices in US

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight loss versus the anticipated 25%.

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is rolling out new data on a higher-dose injection in obesity. | In the phase 3b STEP UP study,

Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight patients lower their weight by 20.7%.

The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction Act. | The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction Act.

Novo Holdings, the controlling shareholder of Novo Nordisk , hopes to double the size of its recently acquired contract drugmaker Catalent over five years, a senior partner at the investment firm said,